Drug Trial Radar · NCT06373406
A Study of MHB036C for Advanced Solid Tumor
Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
May 26, 2023
Primary completion
Apr 2027
Study completion Apr 2027
Sponsor
- Lead sponsor
- Minghui Pharmaceutical (Hangzhou) LtdIndustry
- Sponsor type
- Industry
- First posted
- Apr 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase I/II, dose escalation and dose expansion study to evaluate the efficacy and safety of MHB036C in advanced malignant tumors.
Conditions
- Advanced Solid Tumor
Interventions
MHB036CDrug
An antibody-drug conjugate therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of participants with adverse events (AE)Time frame: Until 30 days after last dose of MHB036C
- Number of participants with dose-limiting toxicity (DLT)Time frame: At the end of Cycle 1 (each cycle is 21 days)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Chest Hospital
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.